Asa Henin

Asa’s practice is focused on the ongoing representation of publicly traded life sciences companies as primary outside corporate and securities counsel.  He advises management and boards of directors on SEC reporting and disclosure requirements, proxy statements and shareholder meetings, stock exchange requirements, corporate governance, communications with investors, and other corporate and securities matters.  Asa also advises companies in connection with their pre-IPO crossover financings, initial public offerings and follow-on public offerings, as well as PIPE (private investment in public equity) financings.  He is a member of Cooley’s Public Company Advisory Team (PCAT).

Representative transactions include:

• Allogene Therapeutics – $372.6 million IPO
• Arena Pharmaceuticals – $405.7 million Public Offering
• Kronos Bio – $287.5 million IPO 
• Travere Therapeutics –  $230.0 million follow-on equity offering